Literature DB >> 21233532

Important advances in the field of anti-dengue virus research.

Justin G Julander1, Stuart T Perry, Sujan Shresta.   

Abstract

There are currently no licensed antivirals available for the treatment of dengue virus (DENV), which causes significant morbidity and mortality throughout tropical areas of the world and is now encroaching on the southern United States. Recent improvements in existing animal models and cell culture systems have been very important in elucidating the mechanisms of DENV pathogenesis in humans, including the identification of potential viral and host proteins that might be targeted for the treatment of DENV infection. The AG129 mouse model is a major advance in the development of antiviral and vaccine candidates for clinical use. It allows for testing of potential therapeutics in a relevant system that exhibits some aspects of disease that are similar to those observed in humans. This review focuses on recent developments in the AG129 mouse model and discusses compounds that have been found to be active in available cell and animal model systems within the past year.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233532     DOI: 10.3851/IMP1690

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  13 in total

1.  A single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viral RNA synthesis.

Authors:  Dixon Grant; Grace K Tan; Min Qing; Jowin K W Ng; Andy Yip; Gang Zou; Xuping Xie; Zhiming Yuan; Mark J Schreiber; Wouter Schul; Pei-Yong Shi; Sylvie Alonso
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Evaluation of antiviral therapies in respiratory and neurological disease models of Enterovirus D68 infection in mice.

Authors:  Brett L Hurst; W Joseph Evans; Donald F Smee; Arnaud J Van Wettere; E Bart Tarbet
Journal:  Virology       Date:  2018-10-31       Impact factor: 3.616

3.  Mathematical modeling of dengue epidemic: control methods and vaccination strategies.

Authors:  Sylvestre Aureliano Carvalho; Stella Olivia da Silva; Iraziet da Cunha Charret
Journal:  Theory Biosci       Date:  2019-02-10       Impact factor: 1.919

4.  Virus antibody dynamics in primary and secondary dengue infections.

Authors:  Tanvi P Gujarati; G Ambika
Journal:  J Math Biol       Date:  2014-01-04       Impact factor: 2.259

5.  The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus.

Authors:  Hui-Wen Chen; Kevin King; Jui Tu; Marisa Sanchez; Andrew D Luster; Sujan Shresta
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

6.  Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases.

Authors:  Huiguo Lai; Dengfeng Dou; Sridhar Aravapalli; Tadahisa Teramoto; Gerald H Lushington; Tom M Mwania; Kevin R Alliston; David M Eichhorn; Radhakrishnan Padmanabhan; William C Groutas
Journal:  Bioorg Med Chem       Date:  2012-11-15       Impact factor: 3.641

7.  Updates on clinical pharmacology of dengue.

Authors:  Viroj Wiwanitkit
Journal:  Indian J Pharmacol       Date:  2013 Jan-Feb       Impact factor: 1.200

8.  The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.

Authors:  Adriana S Azevedo; Antônio J S Gonçalves; Marcia Archer; Marcos S Freire; Ricardo Galler; Ada M B Alves
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

9.  Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry.

Authors:  Liang-Tzung Lin; Ting-Ying Chen; Song-Chow Lin; Chueh-Yao Chung; Ta-Chen Lin; Guey-Horng Wang; Robert Anderson; Chun-Ching Lin; Christopher D Richardson
Journal:  BMC Microbiol       Date:  2013-08-07       Impact factor: 3.605

10.  Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2.

Authors:  Marlen Martinez-Gutierrez; Luis A Correa-Londoño; Jaime E Castellanos; Juan C Gallego-Gómez; Jorge E Osorio
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.